Genome Technology Magazine Honors DNAPrint's Dr. Tony Frudakis as Most Influential Scientist for SNPs or Genotyping
SARASOTA, Fla.--(BUSINESS WIRE)--June 27, 2001--DNAPrint genomics, Inc. (OTCBB:DNAP) is proud to announce that Dr. Tony Frudakis, the Company's CSO/CEO, was awarded the Most Influential Scientist in SNPs or Genotyping by Genome Technology Magazine.
Other award winners include: Eric Lander of the Whitehead Institute Center and Craig Venter of Celera Genomics (CRA) as the Most Influential Scientists in the Genomics field; Elliott Sigal of Bristol Myers Squibb (BMY) in the Big Pharma category; Michael Hunkapiller, President of Applied Biosystems (ABI), for Genomics Tools Development; Gene Myers of Celera Genomics (CRA) for Bioinformatics; John Yates of the Scripps Research Institute for Proteomics; and Pat Brown of Stanford University for Gene Expression.
Award winners were selected in an online ballot by the magazine's readers--more than 15,000 genomics researchers, scientists, and business people.
Genome Technology's July issue, which is being mailed this week, features interviews with each of the winners and a list of 39 runners-up. Awards will be presented to the winners at the Genome Technology All-Stars Awards Bash on October 26 at the Genome Sequencing and Analysis Conference in San Diego. Genome Technology is a monthly magazine for and about the genomics industry. It is published by GenomeWeb, LLC, based in Manhattan.
Subscribe to Genome Technology at genome-technology.com. For a press copy of the magazine's July issue contact: Karen Richmond at 212-269-4747.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company has a focused effort within the population genomics, informatics, and clinical data fields for the application and production of novel personalized medicine products.
The Company has, year-to-date, finished building its discovery infrastructure, and is now devoting its resources to operating this infrastructure for the generation of genomics-based classification and diagnostics products.
We have developed a high-throughput SNP discovery engine that has allowed us to discover about 1 novel, quality validated SNP for every 200 bases of target sequence in the human genome. We have found the average gene to contain over 30 SNPs within its promoter, 3'UTRs, exons and flanking intron sequences - a rate of discovery that is greater than others have previously reported. Relatively few of the SNPs comprising these maps are present in public genome database resources. In addition, analysis conducted to date have validated these SNPs as real polymorphisms at a significantly higher rate than those mined from public database resources. The Company attributes these desirable outcomes to its implementation of unique vertical re-sequencing protocols and proprietary software platform (the patent pending SniPdoc(TM) system) for raw SNP discovery.
In addition to enabling SNP discovery, the proprietary Snipdoc(TM) system enables the Company to qualify markers that may be linked to a patient's response to specific drugs. The company is using proprietary algorithms to infer haplotypes from raw genotype data and quantitative genetics modeling algorithms to identify relationships between haplotypes and continuously distributed drug reaction traits in the patient population.
The Company is located in Sarasota, Florida and is traded publicly on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit dnaprint.com.
For additional information please contact: Richard Craig Hall at (941) 341-0136.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
For Scientific inquiries:
Tony Frudakis, Ph.D., 941/351-4543
or
Other inquiries:
Richard Craig Hall, 941/341-0136 |
